Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Desallais, Lucille ^a   Bouchez, Caroline ^b   Mouhsine, Hadley ^a   Moreau, Gabriel ^c   Ratsimandresy, Rojo ^c   Montes, Matthieu ^a   Do, Hervé ^c   Quintin Colonna, Françoise ^d   Zagury, Jean François ^a  

^a University of Paris Cité   (France)

^b Toxicologist   (France)

^c Institut Cochin   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE;

ANIMAL; ANTIBODY PRODUCTION; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOLOGY; MACACA FASCICULARIS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; HUMANS; HYPERSENSITIVITY; IMMUNIZATION; INTERLEUKIN-6; MACACA FASCICULARIS; PEPTIDES; RECEPTORS, INTERLEUKIN-6;

EID: 84955609525     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19549     Document Type: Article

References (35)

1. Castell, J. V. et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters 242, 237-239 (1989).
2. Robak, T., Gladalska, A., Stepien, H. & Robak, E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7, 347-353 (1998).
3. Needleman, B. W., Wigley, F. M. & Stair, R. W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35, 67-72 (1992).
4. Solary, E. et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am. J. Hematol. 39, 163-171 (1992).
5. Madhok, R., Crilly, A., Watson, J. & Capell, H. A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Annals of the Rheumatic Diseases 52, 232-234 (1993).
6. Scala, E. et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin. Exp. Immunol. 138, 540-546 (2004).
7. De Lauretis, A. et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. The Journal of Rheumatology 40, 435-446 (2013).
8. Sato, S., Hasegawa, M. & Takehara, K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27, 140-146 (2001).
9. Nachbaur, D. M., Herold, M., Maneschg, A. & Huber, H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann. Hematol. 62, 54-58 (1991).
10. Takagi, N. et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41, 2117-2121 (1998).
11. Kitaba, S. et al. Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma. Am. J. Pathol. 180, 165-176 (2012).
12. Ratsimandresy, R. A., Rappaport, J. & Zagury, J.-F. Anti-cytokine therapeutics: history and update. Curr. Pharm. Des. 15, 1998-2025 (2009).
13. Rubbert-Roth, A. & Finckh, A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review. Arthritis Res Ther 11 Suppl 1, S1 (2009).
14. Emi Aikawa, N., de Carvalho, J. F., Artur Almeida Silva, C. & Bonfá, E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38, 82-89 (2010).
15. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
16. Delavallée, L., Duvallet, E., Semerano, L., Assier, E. & Boissier, M.-C. Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 140, w13108 (2010).
17. Desallais, L. et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 16, R157 (2014).
18. Bouchez, C. et al. Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey. J Toxicol Pathol 25, 183-188 (2012).
19. Tassone, P. et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 11, 4251-4258 (2005).
20. Galle, P. et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. International Immunopharmacology 7, 1704-1713 (2007).
21. Ciapponi, L. et al. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat. Biotechnol. 15, 997-1001 (1997).
22. Szepietowski, J. C. et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65, 2661-2671 (2013).
23. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease?. Gastroenterology 126, 989-996 (2004).
24. Sieper, J. et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebocontrolled study (ALIGN). Annals of the Rheumatic Diseases 74, 1051-1057 (2015).
25. Voorhees, P. M. et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161, 357-366 (2013).
26. Spohn, G. et al. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38, 877-887 (2008).
27. Röhn, T. A. et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36, 2857-2867 (2006).
28. Spohn, G. et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178, 7450-7457 (2007).
29. Le Buanec, H. et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. USA. 103, 19442-19447 (2006).
30. Delavallée, L. et al. Active immunization to tumor necrosis factor-? is effective in treating chronic established inflammatory disease: A long-term study in a transgenic model of arthritis. Arthritis Res Ther 11, R195 (2009).
31. Lauwerys, B. R. et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon-kinoid. Arthritis Rheum 65, 447-456 (2013).
32. Waterston, A. M. et al. Phase I study of TNF? AutoVaccIne in Patients with metastatic cancer. Cancer Immunol Immunother 54, 848-857 (2005).
33. Capini, C. J. et al. Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies crossreacting with the native cytokine and in vivo protection. Vaccine 22, 3144-3153 (2004).
34. Bertin-Maghit, S. M. et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 23, 4228-4235 (2005).
35. Ratsimandresy, R. A. et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine 29, 9329-9336 (2011).